Newly published research offers a novel technique to address a classic problem.
Several of the latest cell-based gene and cancer therapies suffer similar drawbacks. The first is that cell manipulation occurs outside the body, a lengthy process that requires extracting, purifying, and altering cells in a specialized lab before reintroducing the treatment to the bloodstream. The second risk for donor-derived, allogeneic therapies is tissue rejection; this occurs…
Continue Reading
News Source: www.forbes.com